SEC Form SC 13G/A filed by Harvard Bioscience Inc. (Amendment)

2/16/23 3:11:00 PM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $HBIO alert in real time by email

SC 13G/A 1 hbio13g.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2022** (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. **This Schedule 13G/A amends and restates the Schedule 13G filed by the Reporting Persons on February 15, 2023 in its entirety. The information required in the remainder of this cover page shall not be deemed to be 'filed' for the purpose of Section 18 of the Securities Exchange Act of 1934 ('Act') or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1 NAME OF REPORTING PERSON B. Riley Asset Management LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 3,264,796 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 3,264,796 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,264,796 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.8% 12 TYPE OF REPORTING PERSON IA 1 NAME OF REPORTING PERSON Wes Cummins 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 3,264,796 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 3,264,796 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,264,796 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.8% 12 TYPE OF REPORTING PERSON IN Item 1(a). NAME OF ISSUER Harvard Bioscience, Inc. Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES 84 October Hill Road, Holliston, MA 01746 Item 2(a). NAME OF PERSON FILING This statement is filed by: (i) B. Riley Asset Management LLC, a Delaware limited partnership ('BRAM'), with respect to the shares of Common Stock directly held by 272 Capital Master Fund Ltd. ('Fund') to which BRAM acts as investment manager, and other advisory accounts of BRAM and (ii) Wes Cummins ('Mr. Cummins', and together with BRAM, the 'Reporting Persons'), who is the President of BRAM. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE The address of the business office of each of the Reporting Persons is 3811 Turtle Creek Blvd, Suite 2125, Dallas, TX 75219. Item 2(c). CITIZENSHIP B. Riley Asset Management LLC is a Delaware limited partnership. Mr. Cummins is a United States citizen. Item 2(d). TITLE OF CLASS OF SECURITIES Common Stock, par value $0.01 per share (the 'Common Stock') Item 2(e). CUSIP NUMBER 416906105 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a)[ ] Broker or dealer registered under Section 15 of the Act; (b)[ ] Bank as defined in Section 3(a)(6) of the Act; (c)[ ] Insurance company as defined in Section 3(a)(19) of the Act; (d)[ ] Investment company registered under Section 8 of the Investment Company Act of 1940; (e)[x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f)[ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii) (F); (g)[x] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h)[ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i)[ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j)[ ] A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. OWNERSHIP The percentages set forth herein are calculated based upon 41,657,688 shares of Common Stock outstanding as of October 31, 2022 as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed by the Issuer with the Securities and Exchange Commission on November 8, 2022. The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference. Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS Not applicable. Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON See Item 2. 272 Capital Master Fund Ltd. has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock. Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON Not applicable. Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable. Item 9. NOTICE OF DISSOLUTION OF GROUP Not applicable. Item 10. CERTIFICATION Each Reporting Person hereby makes the following certification: By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. DATE: February 16, 2023 B. Riley Asset Management LLC By: /s/ Wes Cummins Name: Wes Cummins Title: President Wes Cummins By: /s/ Wes Cummins Name: Wes Cummins

Get the next $HBIO alert in real time by email

Date

Price Target

Rating

Analyst

4/9/2025

Overweight → Sector Weight

KeyBanc Capital Markets

3/10/2023

$3.00 → $4.00

Speculative Buy → Buy

The Benchmark Company

SEC Form SC 13G/A filed by Harvard Bioscience Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$HBIO

$HBIO
Leadership Updates

Live Leadership Updates

Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer

$HBIO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Harvard Biosci downgraded by KeyBanc Capital Markets

Harvard Biosci upgraded by The Benchmark Company with a new price target

KeyCorp reiterated coverage on Harvard Bioscience with a new price target

$HBIO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Green James W bought $29,100 worth of shares (10,000 units at $2.91), increasing direct ownership by 0.32% to 3,111,091 units (SEC Form 4)

Green James W bought $61,400 worth of shares (20,000 units at $3.07), increasing direct ownership by 0.65% to 3,101,091 units (SEC Form 4)

$HBIO
Press Releases

Fastest customizable press release news feed in the world

Harvard Bioscience Announces First Quarter 2025 Financial Results

Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

Harvard Bioscience Announces CFO Transition

$HBIO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$HBIO
SEC Filings

Interim CFO Frost Mark T was granted 100,000 shares, increasing direct ownership by 400% to 125,000 units (SEC Form 4)

New insider Frost Mark T claimed ownership of 25,000 shares (SEC Form 3)

Chief Financial Officer Cote Jennifer covered exercise/tax liability with 5,687 shares, decreasing direct ownership by 3% to 159,019 units (SEC Form 4)

Amendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.

SEC Form SD filed by Harvard Bioscience Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.

$HBIO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Harvard Bioscience Inc.

SEC Form SC 13G filed by Harvard Bioscience Inc.